ClinicalTrials.gg
CompletedNCT04073303Updated May 6, 2025Results posted

BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence

A Phase 3 interventional study of Botulinum Toxin Type A and Placebo in Masseter Muscle Prominence, sponsored by AbbVie. Completed at 21 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to evaluate the safety and effectiveness of administering BOTOX for the treatment of Masseter Muscle Prominence (MMP) in adults.

02

Conditions studied

  • Masseter Muscle Prominence
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria:

  • Masseter prominence at the Day 1 visit
  • ≤ 30 kg/m2 using the calculation: BMI = weight (kg)/[height (m)]2
  • A female participant must be willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up periods

Exclusion Criteria:

  • Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function
  • An anticipated need for surgery or overnight hospitalization during the study
  • An anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)
  • History of dental or surgical procedure for lower facial shaping or masseter muscle reduction
  • Prior mid-facial and/or lower facial treatment with nonpermanent soft tissue fillers, synthetic implantations, autologous fat transplantation, fat-reducing injectables, and/or skin-tightening laser treatments within 6 months prior to Day 1
  • Prior exposure to botulinum toxin of any serotype to the masseter muscle or lower face at any time, or to any other part of the body within the 6 months prior to Day 1
  • History of temporomandibular joint disorder (TMJD)
  • Masseter prominence due to other etiologies (eg, parotid gland infection, parotiditis, )
  • Known allergy or sensitivity to any of the components of the study treatments or any materials used in the study procedures
  • History of alcohol or drug abuse within 12 months of Day 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
377 participants (actual)

Study arms

  • Active comparator
    Botulinum Toxin Type A (BOTOX®)

    Botulinum Toxin Type A (BOTOX ®) will be administered on Day 1 as bilateral intramuscular injections into the masseter with the possibility of 2 additional treatments

    Biological: Botulinum Toxin Type A

  • Placebo comparator
    Placebo

    Placebo (normal saline) will be administered on Day 1 as bilateral intramuscular injections into the masseter

    Other: Placebo

Interventions

  • Day 1 Administration of bilateral intramuscular injections into the masseter

    Also known as: OnabotulinumtoxinA, BOTOX®

  • OtherPlacebo

    Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter

06

What researchers measure

Primary outcomes

  1. Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90

    Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.

    Time frame: Day 90

Secondary outcomes

  1. Achievement of MMPS Grade ≤ 3 at Day 90

    Proportion of participants who achieve MMPS Grade of ≤ 3 at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.

    Time frame: Day 90

  2. Achievement of MMPS-P Grade ≤ 3 on Day 90

    Proportion of participants who achieve MMPS-P Grade ≤ 3 at Day 90, according to participant, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.

    Time frame: Day 90

  3. Achievement of MMPS-P ≥ 2-Grade Improvement From Baseline at Day 90

    Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.

    Time frame: Day 90

  4. Achievement of PSAC Grade ≥ 1 (at Least Minimally Improved From Baseline) on Day 90

    Proportion of participants who achieve Grade ≥ 1 on Participant Self-Assessment of Change (PSAC) (at least minimally improved from baseline) at Day 90 PSAC ranges from 3 = much improved to -3 = much worse.

    Time frame: Day 90

  5. Change From Baseline in Lower Facial Width (mm) at Day 90

    Calculated from standardized images, measured in millimeters (mm)

    Time frame: Day 90

  6. Median Duration of Effect for MMPS Responders

    Median duration of effect for BOTOX-treated MMPS responders.

    Time frame: Up to Day 360

07

Results

Posted May 6, 2025

Participant flow

A total of 377 participants were enrolled and randomized into the study; 284 to BOTOX and 93 to Placebo. A total of 370 participants were included in the modified ITT (mITT) Population; 278 to BOTOX and 92 to Placebo. A participant was considered to have completed the study if he/she had at least completed the treatment visit and the end of study visit.

Participant flow — Overall Study
MilestonePlaceboBOTOX®
Started93284
Mitt population92278
Completed70240
Not completed2344
Withdrew: Adverse event02
Withdrew: Withdrawal by subject1636
Withdrew: Lost to follow-up61
Withdrew: Protocol deviation04
Withdrew: Other11

Outcome measures

PrimaryAchievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90

Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.

Time frame:
Day 90
Reported as:
Number · percentage of participants
Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 90
percentage of participantsPlaceboBOTOX®
Achievement of ≥ 2-Grade Improvement From Baseline on the Masseter Muscle Prominence Scale (MMPS) at Day 902.2 (0.0 to 5.2)51.2 (45.2 to 57.2)
Statistical analysis
  • Placebo vs BOTOX® · Cochran-Mantel-Haenszel · p = <0.0001 · Rate-difference: 49.0 · 95% CI 40.1 to 54.1
SecondaryAchievement of MMPS Grade ≤ 3 at Day 90

Proportion of participants who achieve MMPS Grade of ≤ 3 at Day 90, per investigator assessments of MMP using the Masseter Muscle Prominence Scale (MMPS). MMPS ranges from 1 = minimal to 5 = very marked.

Time frame:
Day 90
Reported as:
Number · percentage of participants
Achievement of MMPS Grade ≤ 3 at Day 90
percentage of participantsPlaceboBOTOX®
Achievement of MMPS Grade ≤ 3 at Day 909.9 (3.8 to 16.1)81.1 (76.4 to 85.9)
Statistical analysis
  • Placebo vs BOTOX® · Cochran-Mantel-Haenszel · p = <0.0001 · Rate-difference: 71.2 · 95% CI 60.7 to 76.3
SecondaryAchievement of MMPS-P Grade ≤ 3 on Day 90

Proportion of participants who achieve MMPS-P Grade ≤ 3 at Day 90, according to participant, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.

Time frame:
Day 90
Reported as:
Number · percentage of participants
Achievement of MMPS-P Grade ≤ 3 on Day 90
percentage of participantsPlaceboBOTOX®
Achievement of MMPS-P Grade ≤ 3 on Day 9019.5 (11.2 to 27.8)76.2 (71.1 to 81.4)
Statistical analysis
  • Placebo vs BOTOX® · Cochran-Mantel-Haenszel · p = <0.0001 · Rate-difference: 56.7 · 95% CI 45.6 to 64.5
SecondaryAchievement of MMPS-P ≥ 2-Grade Improvement From Baseline at Day 90

Proportion of participants who achieve ≥ 2-grade improvement from baseline at Day 90, per Masseter Muscle Prominence Scale-Participant (MMPS-P) MMPS-P ranges from 1 = not at all pronounced to 5 = very pronounced.

Time frame:
Day 90
Reported as:
Number · percentage of participants
Achievement of MMPS-P ≥ 2-Grade Improvement From Baseline at Day 90
percentage of participantsPlaceboBOTOX®
Achievement of MMPS-P ≥ 2-Grade Improvement From Baseline at Day 909.1 (3.1 to 15.0)58.8 (52.9 to 64.7)
Statistical analysis
  • Placebo vs BOTOX® · Cochran-Mantel-Haenszel · p = <0.0001 · Rate-difference: 49.7 · 95% CI 40.6 to 57.4
SecondaryAchievement of PSAC Grade ≥ 1 (at Least Minimally Improved From Baseline) on Day 90

Proportion of participants who achieve Grade ≥ 1 on Participant Self-Assessment of Change (PSAC) (at least minimally improved from baseline) at Day 90 PSAC ranges from 3 = much improved to -3 = much worse.

Time frame:
Day 90
Reported as:
Number · percentage of participants
Achievement of PSAC Grade ≥ 1 (at Least Minimally Improved From Baseline) on Day 90
percentage of participantsPlaceboBOTOX®
Achievement of PSAC Grade ≥ 1 (at Least Minimally Improved From Baseline) on Day 9020.4 (12.0 to 28.7)90.8 (87.3 to 94.4)
Statistical analysis
  • Placebo vs BOTOX® · Cochran-Mantel-Haenszel · p = <0.0001 · Rate-difference: 70.5 · 95% CI 59.6 to 77.5
SecondaryChange From Baseline in Lower Facial Width (mm) at Day 90

Calculated from standardized images, measured in millimeters (mm)

Time frame:
Day 90
Reported as:
Least squares mean · millimeters (mm)
Change From Baseline in Lower Facial Width (mm) at Day 90
millimeters (mm)PlaceboBOTOX®
Change From Baseline in Lower Facial Width (mm) at Day 90-0.04 ± 0.202-5.24 ± 0.121
Statistical analysis
  • Placebo vs BOTOX® · ANCOVA · p = <0.0001 · Ls mean of difference: -5.19 · 95% CI -5.64 to -4.75
SecondaryMedian Duration of Effect for MMPS Responders

Median duration of effect for BOTOX-treated MMPS responders.

Time frame:
Up to Day 360
Reported as:
Median · Days
Median Duration of Effect for MMPS Responders
DaysBOTOX®
MMPS ≥ 2-Grade Improvement176.0 (154.0 to 183.0)
MMPS Grade ≤ 3213.0 (204.0 to 236.0)
MMPS ≥ 1-Grade Improvement268.0 (239.0 to 304.0)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection/time of informed consent/enrollment (whichever study team prefers per protocol/study design) to the end of the study. The median time on follow-up (or mean time followed) was 539.0 and 540.0 Days for Placebo and BOTOX ®, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/93 (0%)4/93 (4.3%)19/93 (20.4%)
BOTOX®0/283 (0%)11/283 (3.9%)54/283 (19.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlaceboBOTOX®
POST HERPETIC NEURALGIANervous system disorders1/930/283
ENDOMETRIOSISReproductive system and breast disorders1/930/283
NASAL SEPTUM DEVIATIONRespiratory, thoracic and mediastinal disorders1/930/283
ABORTION INDUCEDSurgical and medical procedures1/933/283
VENTRICULAR EXTRASYSTOLESCardiac disorders0/931/283
HAEMORRHOIDSGastrointestinal disorders0/931/283
GALLBLADDER POLYPHepatobiliary disorders0/931/283
POST-ACUTE COVID-19 SYNDROMEInfections and infestations0/931/283
PULMONARY TUBERCULOSISInfections and infestations0/931/283
ABORTION OF ECTOPIC PREGNANCYPregnancy, puerperium and perinatal conditions0/931/283
Most frequent other events
Most frequent other events
EventPlaceboBOTOX®
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations6/9318/283
MASTICATION DISORDERMusculoskeletal and connective tissue disorders6/9314/283
HEADACHENervous system disorders6/9311/283
NASOPHARYNGITISInfections and infestations3/9317/283

Baseline characteristics

Modified Intent-to-Treat (mITT) Population

Age, Continuous
Age, Continuous(years)PlaceboBOTOX®Total
Mean31.0 ± 8.6731.5 ± 8.3531.4 ± 8.42
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBOTOX®Total
Female82244326
Male103444
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboBOTOX®Total
Hispanic or Latino145
Not Hispanic or Latino91274365
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBOTOX®Total
American Indian or Alaska Native000
Asian76247323
Native Hawaiian or Other Pacific Islander011
Black or African American101
White152944
More than one race011
Unknown or Not Reported000
Baseline Masseter Muscle Prominence Scale (MMPS)
Baseline Masseter Muscle Prominence Scale (MMPS)(Participants)PlaceboBOTOX®Total
4 = Marked59177236
5 = Very Marked33101134
08

Study locations

21 sites
  • Duplicate_Beacon Dermatology Inc /ID# 233018
    Calgary, Alberta T3E 0B2, Canada
  • Duplicate_Humphrey Cosmetic Dermatology /ID# 232764
    Vancouver, British Columbia V5Z 4E1, Canada
  • Project Skin MD LTD /ID# 232763
    Vancouver, British Columbia V6H 1K9, Canada
  • Pacific Derm /ID# 233156
    Vancouver, British Columbia V6H 4E1, Canada
  • The Center For Dermatology /ID# 233001
    Richmond Hill, Ontario L4B 1A5, Canada
  • Peking University Third Hospital /ID# 233148
    Beijing, Beijing 100191, China
  • Duplicate_Peking Union Medical College Hospital /ID# 233072
    Beijing, Beijing 100730, China
  • Chinese PLA General Hospital /ID# 233158
    Beijing, Beijing 100853, China
  • Peking University First Hospital /ID# 232973
    Xicheng District, Beijing 100034, China
  • Tianjin Medical University General Hospital /ID# 232961
    Tianjin, Guizhou 300052, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 233008
    Wuhan, Hubei 430022, China
  • Xiangya Hospital Central South University /ID# 233027
    Changsha, Hunan 410008, China
  • Nanjing Drum Tower Hospital /ID# 233016
    Nanjing, Jiangsu 210008, China
  • Zhongda Hospital Southeast University /ID# 232836
    Nanjing, Jiangsu 210009, China
  • Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine /ID# 232656
    Shanghai, Shanghai 200011, China
  • Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 233087
    Xi'an, Shanxi 710038, China
  • West China Hospital, Sichuan University /ID# 233107
    Chengdu, Sichuan 610041, China
  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 233033
    Kaohsiung, Keelung 807, Taiwan
  • National Taiwan University Hospital /ID# 233133
    Taipei City, Taipei 100, Taiwan
  • Taipei Medical University Hospital /ID# 233009
    Taipei City, 11031, Taiwan
  • Tri-Service General Hospital /ID# 233080
    Taipei City, 11490, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Nov 2022, 38 months.

Results were first posted in May 2025, 2 years 5 months after primary completion. A results delay was requested in Oct 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2019
First posted
Aug 29, 2019
StartActual
Aug 29, 2019
Primary completionActual
Nov 10, 2022
CompletionActual
Nov 10, 2022
Results delay requested
Oct 10, 2023
Results first posted
May 6, 2025
Last update
May 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04073303
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Aug 29, 2019
Start date
Aug 29, 2019
Primary completion
Nov 10, 2022
Completion
Nov 10, 2022
Results posted
May 6, 2025
Last update
May 6, 2025

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion